

IMMUNOCORE

targeting T cell receptors

PRESS RELEASE – IMMUNOCORE LIMITED

Immunocore Wins Private UK Life Science Company of the Year at Biotech and Money Assembly and Awards.

(Oxford, UK, 07 September 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, is delighted to announce that it won the “Private UK Life Science Company of the Year” award at the 2016 Biotech and Money Assembly and Awards. Eliot Forster, Chief Executive Officer of Immunocore was also named “UK Life Science CEO of the Year” at the event.

Dr Eliot Forster, Chief Executive Officer of Immunocore, commented: *“We are delighted to have been presented with these awards, particularly given the calibre of the other nominees. This has been an important period for Immunocore and these awards reflect the great progress we have made in developing our ImmTAC technology over the last year. I would like to thank the Immunocore team for their hard work, dedication and support throughout the past year.”*

For more information, please contact:

Immunocore

Eliot Forster, Chief Executive Officer

T: +44 (0)1235 438600

E: info@immunocore.com

Consilium Strategic Communications

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton

T: +44 (0)203 709 5700

E: Immunocore@consilium-comms.com

Notes for editors

About Immunocore

Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases. Immunocore, based on decades of world-leading scientific innovation in the discovery of HLA targets and T cell receptor technology, has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data, validated by collaborations with world-leading pharmaceutical companies. Immunocore aims to leverage the utility of its platform across a wide range of indications to become a Premier Biotech company and world-leader in its field.

IMMUNOCORE

targeting T cell receptors

Immunocore's world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech and GlaxoSmithKline, via discovery collaborations, MedImmune, the biologics division of AstraZeneca, with which Immunocore has a clinical combination study collaboration as well as a co-discovery and co-development partnership with Lilly. Founded in 2008 originally out of Oxford University and headquartered outside Oxford, Immunocore now has close to 280 staff. Immunocore is well funded and owned by a group of long-term private investors. For more information, please visit www.immunocore.com.

About ImmTACs

Immunocore's proprietary technology is focused on small protein molecules called ImmTACs (Immune mobilising mTCR Against Cancer) that enable the immune system to recognise and kill cancerous or bacterially/virally infected cells.

Immunocore's ImmTACs, a new class of drug with ultra-high affinity for intracellular cancer targets, are synthetic, soluble T cell receptors (TCRs) that recognise diseased cells containing disease specific targets. The ImmTACs enable circulating T-cells to selectively identify and kill diseased cells. The ImmTAC platform is unique in its high specificity and potency and broad applicability to a wide range of intracellular targets and disease indications. ImmTACs can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies.

TCRs naturally recognise diseased cells and Immunocore's world-leading competitive advantage is its ability to engineer high affinity TCRs and link them to an antibody fragment that activates a highly potent and specific T cell response to recognise and destroy cancer cells. The most advanced ImmTAC, IMCgp100, is currently in Phase IIa clinical trials for the treatment of late stage melanoma. Immunocore has a growing internal pipeline of ImmTACs addressing many different cancer types and has developed a broad database of intracellular cancer targets.

ImmTACs can address a significantly larger range of disease indications than currently respond to existing immuno-oncology agents and combine the characteristics of very high potency, encouraging safety and low cost of goods.